Rtw Investments Adds $365M in Tango Therapeutics, Inc. ($TNGX)

RTW Investments has significantly increased its stake in Tango Therapeutics, Inc. (NasdaqGM: TNGX), as revealed in its latest Form 13F filing with the SEC. The fund added approximately 11.8 million shares during the reporting period, boosting its holdings by 792% to a total of 13.3 million shares. This position is valued at around $396.5 million.

What Changed in RTW Investments' Tango Therapeutics Position

RTW Investments made a substantial move by increasing its holdings in Tango Therapeutics from about 1.49 million shares to 13.3 million shares. This represents an increase of 11.8 million shares, or 792%. The current value of this position is approximately $396.5 million, indicating a strong vote of confidence in the company's future.

Other Institutional Activity in Tango Therapeutics

Several other institutional investors have also adjusted their positions in Tango Therapeutics. Adage Capital Partners GP, L.L.C. added 2.2 million shares, bringing its total to 12.8 million shares valued at $267.97 million. Boxer Capital Management, LLC maintained its position with 10.9 million shares worth about $227.53 million. Meanwhile, TCG Crossover Management, LLC reduced its stake by 2.2 million shares, leaving it with 10.5 million shares valued at $220.31 million. FMR LLC significantly increased its holdings by 7 million shares, ending with just under 10 million shares valued at $207.23 million.

Tango Therapeutics Stock Snapshot

Shares of Tango Therapeutics are currently trading around $29.81. The company has a market capitalization of approximately $5.04 billion. Due to its negative earnings, it has no meaningful P/E ratio, but it does have a beta of 1.194, suggesting some volatility. The stock has seen a 52-week low of $4.40 and a high of $32.79. Its 50-day moving average is $23.50, while the 200-day moving average is $13.85. The company boasts a strong current ratio of 27.38 and a quick ratio of 26.51, with a debt-to-equity ratio of 8.38.

Recent Earnings

Tango Therapeutics reported revenue of $56.99 million, but it is not yet profitable, with a net margin of -188.15% and a return on equity of -38.42%. The company is scheduled to release its next earnings report on May 13, 2026.

Insider Buying and Selling at Tango Therapeutics, Inc.

Insider activity at Tango Therapeutics shows several recent purchases. On June 5, 2026, insiders Mace Rothenberg, Sung Lee, Lesley Ann Calhoun, and John Ketchum bought shares, with Rothenberg and Ketchum each purchasing an additional 25,000 shares.

Analysts Set New Price Targets

Analysts have been active in setting new price targets for Tango Therapeutics. Canaccord Genuity maintained a 'buy' rating with a $42 target on June 11, 2026. HC Wainwright & Co. also maintained a 'buy' with a $66 target on June 9, 2026. Meanwhile, Piper Sandler downgraded the stock to 'hold' with a $24 target on May 15, 2026. The consensus rating remains strong, with an average target price of $40.45 among 11 analysts.

About Tango Therapeutics

Tango Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts. It focuses on precision oncology, developing drugs for specific patient populations with unmet medical needs. The company's pipeline includes PRMT5 inhibitors like TNG462 for pancreatic and lung cancers and TNG456 for glioblastoma. Founded in 2017, Tango Therapeutics is led by CEO Dr. Malte Peters and employs 137 people.

Bottom Line

RTW Investments' substantial increase in Tango Therapeutics highlights the fund's confidence in the company's prospects. Investors often track such significant institutional moves for potential insights, but it's important to remember that 13F filings are backward-looking and may not reflect current positions. With a strong pipeline in precision oncology, Tango Therapeutics remains a company to watch in the biotechnology sector.